Rosetta Prices IPO Below Previously Lowered Range; miRNA R&D Plans Remain Unchanged
March 01, 2007
Rosetta Prices IPO Below Previously Lowered Range; miRNA R&D Plans Remain Unchanged
Though it has priced its IPO $0.50 below a previously lowered range, the company has not made any changes to how it plans to spend the proceeds on research and development activities.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News